TRT and Prostate Health: What the Updated PSA Safety Data Actually Shows
Fear of prostate cancer has kept many hypogonadal men off TRT for decades -- but the 2023 TRAVERSE trial, the largest TRT RCT ever conducted with 5,000+ participants, found no significant difference in prostate cancer incidence between TRT and placebo groups. Dr. Farhan Abdullah explains the historical Huggins hypothesis that drove prostate fear, Morgentaler's saturation model that reframed the biology, what TRAVERSE actually showed, why PSA monitoring remains essential despite the reassuring cancer data, and the PSA trajectory thresholds that trigger urologic evaluation in the TRT program at Magnolia Functional Wellness.
By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX
Fear of prostate cancer has kept more men off TRT than almost any other concern, and for decades that fear had a specific scientific foundation -- or at least appeared to. Testosterone feeds prostate cancer cells. Castration (eliminating testosterone) has been a mainstay of prostate cancer treatment for 80 years. Therefore, giving testosterone to men with prostate cancer would be catastrophic, and even giving it to men without prostate cancer might promote subclinical disease. That was the dominant clinical thinking for most of the 20th century.
The evidence has shifted substantially. I'm Dr. Farhan Abdullah at Magnolia Functional Wellness in Southlake, and the prostate safety data for TRT is one of the most important conversations I have with patients.
Where the Fear Came From: The Huggins Hypothesis
The original concern traces to Charles Huggins' Nobel Prize-winning work in the 1940s showing that castration caused prostate cancer regression and testosterone administration caused progression -- in men who already had metastatic prostate cancer. The extrapolation from metastatic disease to normal physiology was made, widely adopted, and largely went unchallenged for decades.
The problem is that this extrapolation was flawed. Prostate cancer behavior at supraphysiologic testosterone levels and at physiological levels are different phenomena. Abraham Morgentaler's saturation model, developed over the past two decades, proposes that prostate tissue has a saturable androgen receptor capacity -- once occupied at physiological testosterone levels, additional testosterone beyond that threshold doesn't continue stimulating prostate growth. This explains why men with high-normal testosterone don't have higher prostate cancer rates than men with low testosterone -- a finding that consistently contradicts the older model.
What the Modern Evidence Shows
The TRAVERSE trial -- the largest randomized controlled trial of TRT ever conducted, published in the New England Journal of Medicine in 2023 -- enrolled over 5,000 men with hypogonadism and followed them for a median of 33 months. The trial found no significant difference in prostate cancer incidence between the TRT and placebo groups. It also found no significant difference in prostate cancer-related mortality, high-grade prostate cancer rates, or acute urinary retention events.
This is the most rigorous evidence available and it directly refutes the longstanding assumption that TRT meaningfully increases prostate cancer risk in hypogonadal men. The signal that was feared simply wasn't present at the statistical power the TRAVERSE trial was designed to detect.
PSA Monitoring: Still Essential
The fact that TRT doesn't appear to cause prostate cancer doesn't mean we stop monitoring PSA. TRT can cause modest PSA increases in the first few months of treatment as the prostate responds to improved androgenic stimulation -- this is a normal expected response, not a cancer signal. What matters is the trajectory over time, not a single value.
Our TRT program at Magnolia Functional Wellness monitors PSA at baseline, at three months, and at each annual follow-up. A PSA rise that's stable and modest over time is expected. A PSA that rises rapidly, exceeds 4.0 ng/mL, or produces a PSA velocity (rate of rise) above 0.75 ng/mL per year warrants urologic evaluation. The monitoring framework is what catches the cases that need attention -- not avoiding TRT altogether.
Active Prostate Cancer: Still a Contraindication
The updated evidence changes the picture for hypogonadal men without prostate cancer. It does not change the picture for men with active, untreated prostate cancer -- TRT remains contraindicated in that setting. Men with treated, low-risk prostate cancer in remission represent a more nuanced situation where TRT may be appropriate under urologic co-management; this is an evolving area of clinical practice.
The bottom line: the prostate cancer fear that has denied many hypogonadal men access to a treatment that would meaningfully improve their quality of life is not supported by the best available evidence. Appropriate monitoring remains essential -- but appropriate monitoring, not avoidance, is the right framework.
Your Questions Answered
Led by trained medical professionals delivering safe, effective, and scientifically backed aesthetic and wellness treatments.
The best available evidence says no. The TRAVERSE trial published in 2023 followed over 5,000 men on TRT for nearly three years and found no significant increase in prostate cancer incidence, high-grade cancer, or prostate cancer mortality compared to placebo. The older fear traces back to 1940s research on men with metastatic disease and doesn't reflect how TRT affects hypogonadal men today. That said, active untreated prostate cancer remains a contraindication, which is why we do baseline PSA and DRE screening at Magnolia Functional Wellness before starting any TRT protocol.
A modest PSA rise in the first three to six months of TRT is normal and expected as prostate tissue responds to improved androgen levels. What we're watching for isn't a single number, it's the trajectory over time. At Magnolia Functional Wellness we monitor PSA at baseline, at three months, then annually. A PSA velocity above 0.75 ng/mL per year, a value crossing 4.0 ng/mL, or an unexplained rapid rise triggers a urology referral, not TRT discontinuation. The monitoring is what keeps you safe, not avoiding the therapy.
What are the real risks of TRT and how are they managed?
Erythrocytosis (elevated hematocrit): testosterone's erythropoietic effect can raise red blood cell concentration. Hematocrit above 52–54% increases clotting risk meaningfully. This is monitored at every follow-up; dose reduction or therapeutic phlebotomy addresses elevation before it becomes a clinical problem. Estradiol elevation: aromatization of testosterone to estradiol can cause water retention, mood changes, and erectile dysfunction if unmanaged. Estradiol is checked at follow-up visits; anastrozole is prescribed when elevation is confirmed and symptomatic. Testicular atrophy and sperm suppression: addressed with hCG when fertility preservation matters. Skin reactions at injection or application sites: typically mild and transient. TRT and prostate cancer: TRT does not cause prostate cancer in men with normal baseline prostates. It is contraindicated in active prostate cancer. PSA is monitored annually in men over 40. None of these risks are reasons to avoid appropriately indicated TRT — they're reasons to monitor it properly, which is the clinical standard at Magnolia.
What's the real cardiovascular safety profile of TRT?
The TRAVERSE trial (2023) established that TRT in hypogonadal men with cardiovascular risk does not increase major cardiovascular events compared to placebo. The monitored risks — hematocrit elevation and modest atrial fibrillation increase — are managed through the structured monitoring schedule at every follow-up.
Is Testosterone Replacement Therapy (TRT) safe?
When properly managed, yes — TRT has a well-established safety profile backed by decades of clinical research. The risks that get attention in the media (cardiovascular events, prostate issues, polycythemia) are largely associated with unmonitored use or supraphysiological dosing. At Magnolia Functional Wellness, Dr. Abdullah monitors hematocrit, estradiol, PSA, and lipid panels on a structured schedule precisely because these are the variables that matter. TRT administered by a physician who actually reviews your labs regularly is a very different thing from ordering testosterone online with no follow-up.
Need More Information?
Our team is ready to answer your specific questions and concerns.